XML 27 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Operating activities:      
Net loss $ (18,752,000) $ (7,317,000) $ (6,558,000)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 527,000 522,000 301,000
Gain on sale of fixed asset (5,000)
Stock-based compensation 1,694,000 1,375,000 907,000
Loss on contract modification 2,126,000
Restricted stock compensation issued to officer 182,000 312,000
Fair Value Adjustment of Warrants 4,117,000 (1,946,000) (2,700,000)
Loss from change in value of option liabilities 2,613,000
Debt discount amortization 373,000
Changes in operating assets and liabilities:      
Trade accounts receivable (65,000) 53,000 132,000
Inventory (307,000) (83,000)
Prepaid expenses and other current assets 96,000 (34,000) 38,000
Other assets (5,000) (3,000)
Accounts payable and accrued liabilities 204,000 337,000 (216,000)
Deferred revenue (64,000) 77,000
Net cash used in operating activities (7,816,000) (6,834,000) (7,419,000)
Investing Activities:      
Purchases of property and equipment (198,000) (675,000) (1,061,000)
Decrease (increase) in restricted cash 2,003,000 (2,008,000)
Proceeds from sale of fixed assets 5,000
Investment in patents and trademarks (22,000) (9,000)
Net cash provided by (used in) investing activities 1,783,000 (2,683,000) (1,065,000)
Financing Activities:      
Proceeds from (repayment of) short-term debt (700,000) 700,000
Proceeds from exercise of stock options 206,000 13,000 205,000
Proceeds from exercise of warrants 226,000
Proceeds from stock issuance, net of issuance costs 62,650,000 1,568,000 16,000,000
Net cash provided by financing activities 62,156,000 2,281,000 16,431,000
Net increase (decrease) in cash 56,123,000 (7,236,000) 7,947,000
Cash at beginning of period 2,773,000 10,009,000 2,062,000
Cash at end of period 58,896,000 2,773,000 10,009,000
Supplemental Schedule of Non-Cash Investing and Financing Activities:      
Cashless exercise of warrants 665,000
Accrued capital expenditures $ 5,000